U.S. Markets
Sarepta Therapeutics (SRPT) reaffirms FY26 sales forecast between USD 1.2-1.4bln; management guides towards lower end of range
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
